製品番号: HY-N8290

ラクチュコピクリン

(別名: Lactupicrin; Lactucopicrin)

カスタマーレビュー

Based on 1 Customer Validation

Lactupicrin (Lactucopicrin) exhibits analgesic, sedative, antimalarial activities and atheroprotective effect. Lactupicrin inhibits acetylcholinesterase (AChE) with an IC₅₀ of 150.3 μM. Lactupicrin is an orally active characteristic bitter sesquiterpene lactone.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.62%
CAS 番号: 65725-11-3
分子式: C₂₃H₂₂O₇
分子量:410.42

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lactupicrin 構造式

CAS 番号: 65725-11-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

NF-κB アイソフォーム固有の製品をすべて表示 :

Cholinesterase (ChE) アイソフォーム固有の製品をすべて表示 :

AChE
BChE

Parasite アイソフォーム固有の製品をすべて表示 :

体外実験

Lactupicrin (0.25-1 μM, 24 h) attenuates cholesterol influx into low-grade inflammatory macrophages by targeting LOX-1^[2].
Lactupicrin (0.625-40 μM, 24 h) reduces NF-κB activities in inflammated macrophages^[3].
Lactupicrin (40 μM, 24 h) inhibits p65 nuclear translocation by downregulation of cytoplasmic dynein-mediated transport of p65 in inflammated macrophages^[3].
Lactupicrin (50 μg/L, 48 h) completely prevents parasite growth^[4].
Lactupicrin (10-1000 μM, 45 min) exhibits AChE inhibition dose-dependently ^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[2]

Cell Line:

low-grade inflammatory macrophages
Concentration:

0.25, 0.5, 1 μM
Incubation Time:

24 h
Result:

Did not form foam cell and cholesterol influx knocked down with LOX-1 and inhibited foam cell formation in cells knocked down with either SR-A or CD36.

Western Blot Analysis^[3]

Cell Line:

Bone marrow-derived macrophages (BMDMs).
Concentration:

10, 20, 40 μM
Incubation Time:

24 h
Result:

Significantly reduced nuclear p65 content at 20 and 40 μM.
Inhibited the interaction of cytoplasmic dynein with p65 at 40 μM.
Did not affect the expression of dynein at 10, 20, 40 μM.

Real Time qPCR^[3]

Cell Line:

Bone marrow-derived macrophages (BMDMs) cells.
Concentration:

10, 20, 40 μM
Incubation Time:

24 h
Result:

Significantly reduced mRNA and protein levels of IL-1β, IL-6, and TNF-α, downstreams of NF-κB at 20 and 40 μM.
Did not affect the mRNA and protein expression of importin-α5 at 10-40 μM.
Did not affect the expression of dynein.

体内実験

Lactupicrin (15-30 mg/kg, i.p.) shows analgesic activities and sedative properties in mice^[1].
Lactupicrin (1.2-120 mg/kg, p.o., daily, 12 weeks) limits macrophage foam cell formation through a reduction of LOX-1 in lipid rafts, contributing to its atheroprotective effect in ApoE^-/- mice^[2].
Lactupicrin (1.2-120 mg/kg, p.o., daily, 12 weeks) inhibits early atherosclerosis formation in ApoE^-/-mice^[3].
Lactupicrin (1.2-120 mg/kg, p.o., daily, 12 weeks) reduces ApoE^-/-mice serum levels of IL-1β and TNF-α but not IL-6 dose-dependently^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Albino Swiss mice, weighing 24-28 g^[1].
Dosage:

15, 30 mg/kg
Administration:

i.p.
Result:

Prolonged the latency towards a noxious stimulus by 142 %.
Showed significant antinociceptive activities.
Decreased the spontaneous locomotor activity at a dose of 30 mg/kg (but not 15 mg/kg).

Animal Model:

ApoE^-/- mice (C57BL/6), 8 weeks old, male, were fed with a high-fat diet (21% milk fat, 0.15% cholesterol)^[2].
Dosage:

1.2, 12, 120 mg/kg
Administration:

p.o., daily, 12 weeks
Result:

Reduced the percentage of F4/80 (a marker to identify macrophage) positive derived foam cells within plaques at the aortic sinus dose-dependently.
Reduced the mRNA levels of Lox1 and F4/80 in aortic arches dose-dependently.

Animal Model:

Male ApoE^-/- mice (C57BL/6), 6-8 weeks old, were fed a high fat diet (21% milk fat, 0.15% cholesterol)^[3].
Dosage:

12, 120 mg/kg
Administration:

p.o., daily, 12 weeks
Result:

Reduced the atherosclerotic plaque area at the sites of both aortic sinus and thoracic and abdominal aortas.
Reduced the percentage of CD68 and F4/80 (two widely used markers to identify macrophages) positive cells within plaques at the aortic sinus.

化学情報

CAS 番号 65725-11-3
性状 Solid
分子量 410.42
分子式 C₂₃H₂₂O₇
Color White to off-white
SMILES

OCC([C@](C1=C2C)([H])[C@](OC3=O)([H])[C@@](C3=C)([H])[C@H](C2)OC(CC(C=C4)=CC=C4O)=O)=CC1=O
別名

Lactupicrin; Lactucopicrin
Structure Classification
- Terpenoids
- Sesquiterpenes
- Phenols
- Monophenols
Initial Source
- Plants
- Compositae
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 250 mg/mL (609.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4365 mL

12.1826 mL

24.3653 mL

5 mM

0.4873 mL

2.4365 mL

4.8731 mL

10 mM

0.2437 mL

1.2183 mL

2.4365 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Wesołowska A, et, al. Analgesic and sedative activities of lactucin and some lactucin-like guaianolides in mice. J Ethnopharmacol. 2006 Sep 19;107(2):254-8. [Content Brief]

[2]. Li Q, et, al. Terpene Lactucopicrin Limits Macrophage Foam Cell Formation by a Reduction of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Lipid Rafts. Mol Nutr Food Res. 2022 Feb;66(4):e2100905. [Content Brief]

[3]. He L, et al. Lactupicrin Inhibits Cytoplasmic Dynein-Mediated NF-κB Activation in Inflammated Macrophages and Alleviates Atherogenesis in Apolipoprotein E-Deficient Mice. Mol Nutr Food Res. 2021 Feb;65(4):e2000989. [Content Brief]

[4]. Bischoff TA, et al. Antimalarial activity of lactucin and lactucopicrin: sesquiterpene lactones isolated from Cichorium intybus L. J Ethnopharmacol. 2004 Dec;95(2-3):455-7. [Content Brief]

[5]. Rollinger JM, et al. Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Curr Drug Discov Technol. 2005 Sep;2(3):185-93. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4365 mL	12.1826 mL	24.3653 mL	60.9132 mL
	5 mM	0.4873 mL	2.4365 mL	4.8731 mL	12.1826 mL
	10 mM	0.2437 mL	1.2183 mL	2.4365 mL	6.0913 mL
	15 mM	0.1624 mL	0.8122 mL	1.6244 mL	4.0609 mL
	20 mM	0.1218 mL	0.6091 mL	1.2183 mL	3.0457 mL
	25 mM	0.0975 mL	0.4873 mL	0.9746 mL	2.4365 mL
	30 mM	0.0812 mL	0.4061 mL	0.8122 mL	2.0304 mL
	40 mM	0.0609 mL	0.3046 mL	0.6091 mL	1.5228 mL
	50 mM	0.0487 mL	0.2437 mL	0.4873 mL	1.2183 mL
	60 mM	0.0406 mL	0.2030 mL	0.4061 mL	1.0152 mL
	80 mM	0.0305 mL	0.1523 mL	0.3046 mL	0.7614 mL
	100 mM	0.0244 mL	0.1218 mL	0.2437 mL	0.6091 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ラクチュコピクリン

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Phenols Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

NF-κB アイソフォーム固有の製品をすべて表示

Cholinesterase (ChE) アイソフォーム固有の製品をすべて表示

Parasite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Lactupicrin 関連分類

HY-N8290 関連分類